Pharmaceuticals & Biotech U.S. Community

Medpace helps smaller drug makers run clinical trials, and its edge comes from doing the whole job end-to-end with deep disease expertise and a global setup that’s hard to copy. But customers can walk away from projects quickly if funding dries up or a trial goes wrong, and the stock already assumes a lot goes right from here.Read more

Lexaria Bioscience is testing multiple drug agents using their DehydraTECH (DHT) technology for oral and topical delivery of medications such as GLP-1and CBD. The DehydraTECH is showing substantial improvement in bioabsorption, brain permeation, taste maksing, and side effect reduction.Read more

A tiny cancer biotech with a shaky cash situation just brought in a leadership team known for big drug deals, while its lead treatment shows early signs of helping the immune system attack hard-to-treat gut cancers. The big question is whether new funding and partners arrive in time to turn promising trial signals and helpful FDA momentum into a real path to approval.Read more

Novo Nordisk atravessa pressão de preços nos EUA, mas a aposta é que o número de doentes tratados no Ocidente ainda está no início e pode crescer muito à medida que mais países começam a comparticipar estes medicamentos. O grande ponto a seguir é se a empresa consegue lançar a próxima geração de tratamentos a tempo e manter o ganho por doente quando as patentes do produto atual expirarem.Read more

The market treats this drug company’s next product updates as almost worthless, even though its lead infection-fighting catheter lock is already widely used and protected for years. The big question is whether upcoming study results and a planned payment reset can lift the business back into favor—or whether a failed trial and a few large customers pulling back could hit hard.Read more

Rhythm Pharmaceuticals is turning a rare genetic obesity medicine into a broader set of uses, and early demand looks stronger than expected as more doctors start prescribing it. On top of that, recent deal activity in similar drug areas suggests the company could become more attractive to a buyer if it keeps executing.Read more

Optimi Health isn’t betting on a single breakthrough study like many psychedelic startups—it already makes and ships regulated psychedelic medicines to researchers and paying patients in places where doctors can prescribe them. The key question is whether its licensing and supply-chain head start can keep paying off as governments decide how fast to open up these treatments.Read more

Eli Lilly’s weight-loss and diabetes drugs are already driving unusually fast growth, but the bigger twist is a next‑generation treatment still in late-stage testing that could expand the company’s reach if results hold up. The upside comes with real pressure from price cuts, tougher reimbursement rules, and the risk that future trial readouts disappoint.Read more

MindWalk Holdings is no longer just a lab-for-hire business—it’s shifting into software that helps drug teams learn from biology data, and the market may not be treating it that way yet. The story hinges on whether its LensAI platform keeps landing sticky enterprise customers and whether its drug programs attract partners without forcing shareholders to fund the bill.Read more